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Background: Lapatinib is a candidate drug for treatment of trastuzumab-
resistant, HER2-positive gastric cancer (GC). Unfortunately, lapatinib 
resistance renders this drug ineffective. The present study investigated the 
implication of forkhead box protein O1 (FOXO1) signaling in the acquired 
lapatinib resistance in HER2-positive GC cells. 
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Methods: Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were 
generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive 
SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression 
were generated by stable transfection of a constitutively active FOXO1 
mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were 
downregulated using RNA interference. The sensitivity of GC cells to 
lapatinib and/or cisplatin was determined by crystal violet assay. In addition, 
Western blot analysis, luciferase reporter assay and RT-PCR were 
performed. 
 
Results: SNU-216 LR cells showed upregulations of HER2 and MET, but 
downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 
overexpression in SNU-216 LR cells significantly suppressed resistance to 
lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 
and MET at the transcriptional level and was negatively controlled by these 
molecules at the post-transcriptional level. A positive crosstalk was shown 
between HER2 and MET, each of which increased resistance to lapatinib 
and/or cisplatin. 
 
Conclusions: FOXO1 serves as an important linker between HER2 and 
 iii 
MET signaling pathways through negative crosstalks, and is a key regulator 
of the acquired lapatinib resistance in HER2-positive GC cells. These 
findings provide a rationale for establishing a novel treatment strategy to 
overcome lapatinib resistance in a subtype of GC patients. 
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Gastric cancer (GC) has been reported to be the fourth most common 
cancer and the second leading cause of cancer-related death worldwide [1]. 
GC is frequently diagnose at an advanced, incurable stage due to its 
asymptomatic feature at its early stage [2]. For these patients, systemic 
chemotherapy is the mainstay of treatment [3]. Although combination 
chemotherapy resulted in substantially improved overall survival compared 
with single-agent chemotherapy, the prognosis of advanced GC remains 
poor [4]. Furthermore, chemotherapy agents target cells that divide rapidly 
and they are unable to discriminate between rapidly dividing normal cells 
and cancer cells, leading to undesirable toxicities [5]. Thus, molecular 
targeted therapy has attracted large attention to improve the specificity of 
targeting cancer cells and significantly reduce non-selective resistance and 
toxicity.  
 
Human epidermal growth factor receptor 2 (HER2/ErbB2/neu) is a 185-
kDa transmembrane receptor tyrosine kinase (RTK) and a member of the 
human epidermal growth factor receptor (HER) family [6]. The HER family 
is made up of four members: HER1, HER2, HER3 and HER4. HER 
proteins exists as monomer on the cell surface. Upon ligands binding to 
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their extracellular domains, HER proteins undergo dimerization and 
transphosphorylation leading to initiation of signal transduction cascade 
that affects cancer cell biology in several ways including by cell proliferation, 
apoptosis, adhesion, migration, and differentiation [7]. Since HER2 is 
unique HER receptor with an ectodomain that maintains an extended 
structure similar to the ligand-bound HER ectodomain, HER2 is a potent 
activator of intracellular signaling upon heterodimer formation with other 
ligand-bound HER proteins [8]. Moreover, HER2-containing heterodimers 
generate intracellular signals that are significantly stronger than signals 
emanating from other HER combinations [9]. In normal cells, few HER2 
molecules exist at the cell surface, so few heterodimers are formed and 
growth signals are relatively weak and controllable. When HER2 is 
overexpressed multiple HER2 heterodimers are formed and cell signaling is 
stronger, resulting in enhanced responsiveness to growth factors and 
malignant growth [9]. This explains why HER2 overexpression is an 
indicator of poor prognosis in various cancers [10] and may be predictive of 
response to treatment. 
 
Regarding GC, HER2 serves as an important therapeutic target for 
therapy in HER2-positive metastatic GC since its overexpression is found in 
more than 15% of GC and is associated with poor prognosis, particularly in 
the advanced stages of disease [11]. A large scale phase III international 
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clinical trial called ToGA showed that the humanized monoclonal antibody 
against HER2, Trastuzumab (Herceptin, Genentech), when combined with 
chemotherapy, could effectively prolong overall survival and progression-
free survival, and increases the response rate in HER2 positive advanced 
GC [11]. On the basis of these findings, trastuzumab combined with 
standard chemotherapy has been used as first-line treatment for patients 
with HER2-positive advanced GC [12]. However, intrinsic and/or acquired 
resistance to trastuzumab became a major obstacle in anti-HER2 therapy 
for advanced GC [11]. Thus, there is a need for alternatives to block HER2 
signaling in GC. 
 
Lapatinib (Tykerb, GlaxoSmithKline, Ware, United Kingdom) is an oral 
dual tyrosine kinase inhibitor, which simultaneously curbs the 
phosphorylation of HER1 and HER2, thus interrupting the HER1/HER2-
associated downstream signaling cascades [13]. A combination and 
capecitabine is used for metastatic HER2-positive breast cancer that is 
refractory to trastuzumab [14]. With regard to GC, a preclinical study 
demonstrated the anti-proliferative effects of lapatinib [15]. However, 
several clinical trial found no benefit from lapatinib for HER2-positive GC 
patients [16-18]. The unsatisfactory results of the lapatinib clinical trials 
suggest the presence of drug resistance mechanisms or alternative 
pathways of escape from lapatinib treatment. Therefore, it is important to 
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know in advance which pathways could mediate resistance to the lapatinib 
treatment and to find ways of bypassing these obstacles [19]. 
 
Mesenchymal-epithelial transition factor protein (MET), the hepatocyte 
growth factor (HGF) receptor, is a 190-kDa RTK, and plays a critical role in 
tumor growth, invasion and metastasis. MET is frequently overexpressed 
and activated in a subset of GC [20]. Previously it has been shown that co-
expression of MET and HER2 in GC is associated with poorer survival 
compared to overexpression of either one [21]. Moreover, MET 
overexpression occurred more frequently in HER2-positive GCs than in 
HER2-negative GCs [22]. Growing evidences implicate the interplays 
between HER family receptors and MET in cancer cells through 
overlapping downstream signaling pathways [19]. In vitro cell culture 
experiments showed that HGF-induced MET activation was responsible for 
lapatinib resistance in HER2-positive GC cell lines [23, 24]. In addition, GC 
cells derived from HER2-positive and MET-positive GC showed that the 
combination of lapatinib and MET-inhibitor offered a more profound cell 
growth inhibition than lapatinib alone [22]. Despite the strong evidence 
regarding the interplay between MET and HER2 in GC, the current 
understanding of the regulation of MET expression and activation in relation 




The forkhead box O (FOXO) family of transcription factors is an 
evolutionally conserved subfamily of forkhead transcription factor and 
consist of FOXO1, FOXO3, FOXO4 and FOXO6 [25]. The first three are 
ubiquitously expressed, at different levels depending on the tissue [26, 27]. 
On the contrary, FOXO6 is expressed only in the central nervous system 
[28]. The expression and activity of FOXO factors are strongly controlled by 
post-translational modifications such as phosphorylation, acetylation, 
methylation and ubiquitination [29]. A major mechanism of regulation of 
FOXOs consists of phosphorylation by AKT, leading to FOXO inactivation 
[30]. In cancer cells, FOXOs control diverse cellular functions by regulating 














Figure 1. FOXO functions in cancer.  
FOXOs are involved in diverse physiological processes, such as cell cycle 
arrest, apoptosis, and oncogene-induced senescence, which prevent tumor 
development and contribute to cancer cell killing by various drugs (green). 
By contrast, FOXOs also play pro-tumoral roles, in the resistance to certain 
treatments, for instance (red). Ambiguous functions of FOXOs have been 
described in angiogenesis, oxidative stress resistance, differentiation, 
cancer stem cell maintenance and the control of cell invasion and 
metastasis (orange). Key target genes are indicated in smaller letters. 




Since FOXO1 is one of the mammalian FOXOs, which is involved in 
variety of biological process [32], dysregulation of FOXO1 would 
subsequently result in various disease states such as cancer. FOXO1 
inactivation has been documented in several cancers, including GC [33], 
and its association with several anti-cancer drugs has increasing attracted 
oncologists' attention [34-36]. In addition, FOXO1 involved in resistance to 
anti-HER2 drugs, trastuzumab [37, 38]. FOXO1 overexpression by stable 
transfection reduced the resistance of trastuzumab in tratuzumab-resistant, 
HER2- positive breast cancer cells [37]. Another study performed in HER2-
positive breast cancer cells sensitive to trastuzumab showed inhibition of 
survivin gene transcription by direct interaction of FOXO1 with survivin 
promoter [38]. Thus, FOXO1 may also regulate lapatinib resistance in 
HER2-positive cancer cells.  
 
Regarding GC, the existence of a negative crosstalk between FOXO1 
and HER2 in parental GC cell lines was previously reported [39]. This 
crosstalk was associated with cancer cell growth, epithelial-mesenchymal 
transition (EMT), cell migration and invasion in vitro as well as 
tumorigenicity and metastasis in vivo [39]. In addition, the inactivation of 
FOXO1 was associated with a good prognosis as well as specific 
clinicopathological factors [40]. FOXO1 decreased GC angiogenesis [40, 
41]. In contrast, FOXO1 enhanced cisplatin resistance in GC cells by 
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activating phosphoinositide 3-kinase (PI3K)/AKT pathway [36]. However, 
the relationship between FOXO1 and anti-HER2 drug resistance in GC has 
not been reported. In the present study, lapatinib-resistant GC cell lines 
(SNU-216 LR 2-8) were generated by chronic exposure to lapatinib and the 
potential role of FOXO1 in lapatinib resistance was examined. In addition, I 
silenced MET and HER2 expression and investigated its implication in the 













Materials and Methods 
 
Cell culture  
A HER2-positive GC cell line SNU-216 was purchased from the Korean 
Cell Line Bank (Seoul, Korea). Cells were maintained in RPMI 1640 
medium (Life Technologies, Grand Island, NY, USA) containing 10% fetal 
bovine serum (FBS; BioWest, Kansas City, MO, USA) in a humidified 
atmosphere containing 5% CO2 at 37°C. 
 
Reagents and antibodies  
Lapatinib was purchased from Cell Signaling Technology (Berverly, MA, 
USA), and cisplatin (CDDP) was purchased from Sigma (St. Louis, MO, 
USA). Antibodies against phospho-HER2Tyr1221/1222 (pHER2, rabbit 
monoclonal), HER2 (rabbit monoclonal), phospho-METTyr1234/1235 (pMET, 
rabbit monoclonal), phospho-AKTSer473 (pAKT, rabbit polyclonal), AKT 
(rabbit polyclonal), and FOXO1 (rabbit monoclonal) were purchased from 
Cell Signaling Technology. Antibodies against MET (rabbit polyclonal), β-
actin (mouse monoclonal) and secondary antibodies, which are horseradish 
peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG, were purchased 




Generation of lapatinib-resistant clones SNU-216 LR from SNU-216 
cells  
SNU-216 cells were cultured in the presence of increasing concentrations 
of lapatinib over a period of 8 months, reaching a final concentration of 10 
μmol/L at the end of this period as described previously [42]. Single-cell 
clonal populations were obtained from a pool of resistant cells by serial 
dilutions. Cells were expanded in RPMI 1640 medium containing 10% FBS 
and lapatinib (1 μmol/L). 
 
Growth inhibition assays  
The viability of cells was measured indirectly using crystal violet assay as 
described by Kim et al. [43]. Cells were seeded in 24-well plates at a 
density of 1 × 104 cells/well for cell growth and cultured for 4 days. To study 
the cytotoxicity effect of drugs, 1.5 × 104 cells were seeded in 24-well plates, 
incubated for 24 hours, and treated for 3 days at 37°C with indicated 
concentrations of drugs dissolved in 0.04% dimethyl sulfoxide (DMSO). 
Control columns contained cells without drug and blank columns contained 
medium alone. Medium was aspirated from the wells followed by washing 
three times with tap water. Attached cells were stained with 0.2% crystal 
violet aqueous solution in 20% methanol for 10 minutes followed by 
washing four times and were air dried. Crystal violet stain was dissolved in 
10% sodium dodecyl sulfate (SDS) for 10 minutes at room temperature, 
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transferred into 96-well plates, and the absorbance was measured at 570 
nm using an enzyme-linked immunosorbent assay reader (Bio-Rad, 
Hercules, CA, USA). The reading of blank columns was subtracted from 
each value. 
 
Western blot analysis  
Western blot analysis was performed as described previously [39]. Proteins 
were obtained when cells were subconfluent (70-80%). Briefly, cell lysates 
in SDS lysis buffer (125 mM Tris-HCl (pH 6.8), 4% SDS, 0.004% 
bromophenol blue, and 20% glycerol) were separated on 10% SDS-
polyacrylamide gel and electrophoretically transferred to PVDF membranes 
(Millipore Corporation, Billerica, MA, USA) blocked with 5% non-fat dry milk 
in phosphate-buffered saline (PBS)-Tween-20 (0.1%, vol/vol) for 1 hour. 
The membranes were then incubated with a primary antibody against 
pHER2 (1:1000), HER2 (1:1000), pMET (1:1000), MET (1:1000), pAKT 
(1:1000), AKT (1:1000), FOXO1 (1:1000), or β-actin (1:1000). Horseradish 
peroxidase-conjugated anti-rabbit IgG (1:2000) or anti-mouse IgG (1:2000) 
was used as a secondary antibody. Enhanced chemiluminescence 
(Amersham, Arlington Heights, IL, USA) was used to detect the 
immunoreactive proteins. Equal protein loading was confirmed by β-actin. 
 




To determine FOXO1 nuclear DNA-binding activity in GC cells, luciferase 
reporter assay was performed as previously described [36]. GC cells were 
seeded in 24-well plates at a density of 3 ×104 cells/well and were 
transiently cotransfected with 0.4 μg forkhead responsive element (FHRE)-
luciferase reporter plasmid (reporter construct in which a small region of the 
Fas ligand promoter contains the three FHREs, Addgene plasmid 1789, 
Addgene Incorp, Cambridge, MA, USA) and 0.4 mg pSV-β-galactosidase 
vector (Promega, Madison, WI, USA), an internal control, using 
Lipofectamine Plus (Life Technologies). Twenty-four hours after transfection, 
assays for luciferase and β-galactosidase were carried out using a Dual-
Luciferase Reporter Assay System (Promega). Luciferase activity was 
measured on an AutoLumat LB 9505c luminometer (Berthold Analytical 
Instruments, Nashua, Germany) and was normalised by β-galactosidase 
activity. 
 
Overexpressing FOXO1 in SNU-216 LR cells  
Overexpressing FOXO1 was done by stable transfection of pcDNA3 
containing human FOXO1A3 mutant gene (Addgene plasmid 13508, 
Addgene Incorp). The plasmid FOXO1A3 encodes a constitutively active 
version of FOXO1 (all three AKT phosphorylation sites are mutated to Ala). 
Each vector (1 μg) was transfected into GC cells using Lipofectamine Plus 
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according to the manufacturer’s instructions. Twenty-four hours after 
transfection, G418 (3 μg/mL) was added to select stable FOXO1A3 clones. 
 
Lentivirus-mediated short hairpin RNA (shRNA) silencing of HER2 
Lentiviral particles containing non-targeting shRNA or HER2 shRNA were 
purchased (Sigma). The sequence of HER2 shRNA was 5’-CCGGTGTCAG 
TATCCAGGCTTTGTACTCGAGTACAAAGCCTGGATACTGACATTTTTG-3’. 
The control shRNA particles contain 4 bp mismatches within the short 
hairpin sequence to any known human or mouse gene. Viral infection was 
performed by incubating GC cells in the culture medium containing lentiviral 
particles for 12 hours in the presence of 5 μg/mL Polybrene (Santa Cruz 
Biotechnology). Pooled puromycin (2 μg/mL)-resistant cells were used for 
further analysis. 
 
MET silencing by stable transfection with shRNA plasmid vector  
For MET silencing, the pGFP-V-RS plasmid vectors containing either 
scrambled shRNA or MET shRNA were purchased from OriGene (Rockville, 
MD, USA). The sequence of MET shRNA was 5′-GCAAGCCAGATTCTGC 
CGAACCAATGGAT-3′. Each vector (1 μg) was transfected into GC cells 
using Lipofectamine Plus according to the manufacturer’s instructions. 
Twenty-four hours after transfection, puromycin (2 μg/mL) was added to 
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select stable MET shRNA clones. 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
RT-PCR was performed to determine the mRNA level of molecules in GC 
cells, and the amplification of β-actin transcripts was used as the control to 
normalize the transcript levels of molecules. Total RNAs were isolated using 
TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), and reverse-transcription 
was performed to synthesize cDNAs in a 20 μl reaction mixture containing 
each gene-specific primer, 1 μg of RNA, 2×reaction buffer, 0.4 μl Taq 
polymerase and 1.2 mM MgCl2. The cDNAs of HER2 transcripts were 
amplified for 28 cycles (30 seconds at 94°C, 30 seconds at 52°C, and 30 
seconds at 70°C), the cDNAs of MET transcripts were amplified for 30 
cycles (30 seconds at 94°C, 30 seconds at 52°C, and 30 seconds at 72°C), 
the cDNAs of FOXO1 transcripts were amplified for 25 cycles (30 seconds 
at 94°C, 1 minute at 57°C, and 1 minute at 72°C), and the cDNAs of β-actin 
transcripts were amplified for 18 cycles (94°C for 30 seconds, 52°C for 30 
seconds, and 70°C for 30 seconds). The PCR cycling numbers had been 
optimized to avoid the amplification saturation. Five μl RT-PCR product was 
separated on 1% agarose gels, which were subsequently stained with 
ethidium bromide. Primer sequences were 5’-GGGAGAGAGTTCTGAGG 
ATT-3’ and 5’-CGTCCGTAGAAAGGTAGTTG-3’ for HER2, 5’-TTGC CAGA 
GACATGTATGATAAAG-3’ and 5’-CCAGCATTTTAGCATTACTT-3’ for MET, 
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5'-GCAGATCTACGAGTGGATGGTC-3' and 5'-AAACTGTGATCCAGGGCT 
GTC-3' for FOXO1, and 5'-ACACCTTCTACAATGAGCTG-3' and 5'-CATGA 
TGGAGTTGAAGGT AG-3' for β-actin. 
 
Statistical analysis  
All experiments were performed using triplicate cultures, and the results 
were expressed as the mean ± standard deviation (s.d.). Statistical 
analyses were conducted using GraphPad Prism software for Windows 7 
(ver. 4, GraphPad Software, San Diego, CA, USA). Data were evaluated by 
two-tailed Student’s t-test. Differences with a P-value < 0.05 were 





Lapatinib-resistant, HER2-positive GC cells exhibit downregulation of 
FOXO1. 
To verify if FOXO1 is involved in the acquired lapatinib resistance in HER2-
positive GC cells, stable lapatinib-resistant GC cell lines SNU-216 LR (LR2-
LR8) were generated from lapatinib-sensitive parental SNU-216 cells. While 
parental SNU-216 cells treated with 10 µmol/L lapatinib displayed an almost 
complete abrogation of growth, the resistant cell lines showed significantly 
lower cell viability reduction than parental cell line (Figure 2A).   
 
Western blot analysis (Figure 2B) confirmed HER2 overexpression and 
low expression of FOXO1 in parental SNU-216 cells as previously reported 
[39]. In SNU-216 LR cells (except LR2) with the acquired lapatinib 
resistance, the expression and activation (manifested by phosphorylated 
forms) of HER2 and MET increased with a more distinctive upregulation of 
MET. Consistently, phosphorylated AKT (common downstream signaling 
protein of HER2 and MET), but not total AKT, increased in SNU-216 LR 
cells. In contrast, FOXO1 protein expression decreased in most of resistant 
cell lines (L3-L8). Downregulation of FOXO1-induced luciferase expression 
in all lapatinib-resistant cell lines was confirmed using the luciferase 
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reporter assay (Figure 2C). In addition, RT-PCR analysis showed that 
mRNA expressions of HER2 and MET were increased in SNU-216 LR cells. 
In contrast, FOXO1 mRNA expression was not changed (Figure 2B). 
 
FOXO1 overexpression reduces resistance to lapatinib.  
To examine whether FOXO1 is related to the acquired lapatinib resistance 
in SNU-216 LR cells (LR3 and LR7), FOXO1 expression was modulated by 
transfection with a construct expressing constitutively active FOXO1 
(FOXO1A3). Cells transfected with empty pcDNA3 vector were generated 
as control. Western blot analysis (Figure 3A) and the luciferase reporter 
assay (Figure 3B) confirmed that FOXO1 expression and transcriptional 
activity were increased in FOXO1A3-transfected cells compared to vector 
control cells. The role of FOXO1 in the acquired lapatinib resistance in 
HER2-positive GC cells was examined by comparing cell growth of SNU-
216 LR cells with or without FOXO1 overexpression using crystal violet 
assay. Treatment of SNU-216 LR3 cells (Figure 3C) with lapatinib (1 
µmol/L) for 72 hours decreased cell viability to ~ 60% in vector cells and ~ 
40% in FOXO1A3-transfected cells compared to untreated cells. This result 
demonstrated a significant difference in the lapatinib cytotoxicity between 
vector control cells and FOXO1A3-transfected cells (P = 0.0099). Similar 




FOXO1 overexpression increases the cytotoxicity of cisplatin alone or 
combined with lapatinib 
I found that parental SNU-216 cells were cisplatin-sensitive, but SNU-216 
LR cells were cisplatin-resistant (Figure 4A). Thus, SNU-216 LR cells with 
lapatinib resistance also developed cross-resistance to cisplatin. However, 
treatment of SNU-216 LR3 cells with cisplatin (10 µg/mL) in the presence of 
FOXO1 overexpression significantly decreased cell viability (52% versus 
the untreated control) compared with vector control cells (93% versus the 
untreated control) (P = 0.0157, Figure 4B). Similar results were shown in 
SNU-216 LR7 cells (P = 0.0075, Figure 4B).  
 
Although lapatinib plus chemotherapy using parental SNU-216 cells 
showed an additive or synergistic effect in vitro [15], inconsistent results 
were shown in the second-line treatment of patients with HER2-positive GC 
[20]. In the present study, the effect of adding cisplatin to lapatinib in SNU-
216 LR3 and LR7 cells in the absence or presence of FOXO1 
overexpression was examined. In the presence of FOXO1 overexpression, 
the combined treatment with cisplatin and lapatinib showed an additive 
cytotoxic effect (26% versus the untreated control) in SNU-216 LR3 cells 
compared to treatment with lapatinib alone (44% versus the untreated 
control) (P = 0.0219). However, there was no difference in cell viability in 
the absence of FOXO1 overexpression (Figure 4C). Consistent results 
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were shown in LR7 cells (P = 0.001, Figure 4C). Thus, FOXO1 induces the 
efficacy of adding cisplatin to lapatinib in lapatinib-resistant SNU-216 LR 
cells. 
 
FOXO1 transcriptionally downregulates HER2 and MET. 
HER2 and MET are strong predictors of lapatinib sensitivity in GC cells [23, 
24, 42]. However, the molecular mechanism underlying a link between 
HER2 and MET with respect to lapatinib resistance remains undefined. To 
analyze the relationship between FOXO1 and HER2/MET in SNU-216 LR 
cells, I increased the FOXO1 expression and activation by transfection of 
FOXO1A3 as shown in Figure 3A and 3B. In addition, Western blot analysis 
and RT-PCR were performed. Western blot analysis showed that the total 
and phosphorylated forms of HER2 and MET were downregulated by 
FOXO1 overexpression (Figure 5A). Furthermore, the protein expression of 
phosphorylated AKT, but not the total AKT, was decreased. Consistently, 
RT-PCR demonstrated that mRNA expressions of HER2 and MET were 
downregulated (Figure 5B). Taken together, FOXO1 negatively regulates 
HER2 and MET expressions at the transcriptional level, suggesting its 
involvement in the lapatinib-induced HER2/MET signaling pathway. 
 




Parental SNU-216 cells are responsive to lapatinib because of the 
presence of HER2 overexpression. In the present study, however, SNU-
216 cells became resistant to lapatinib after chronic exposure to lapatinib in 
spite of HER2 upregulation (Figure 2A and 2B). To investigate whether the 
dependency of cell viability on HER2 expression persists in SNU-216 LR 
cells, HER2 was downregulated by RNAi (Figure 6A). I found that HER2 
shRNA-transfected cells had a lower level of pAKT (Figure 6A) and showed 
growth inhibition (Figure 6B). HER2 downregulation also significantly 
suppressed lapatinib resistance (Figure 6C) and cisplatin resistance (Figure 
6D) compared to control shRNA cells. Furthermore, the combined 
treatment of HER2 shRNA-transfected SNU-216 LR cells showed an 
additive cytotoxic effect compared to treatment with lapatinib alone (Figure 
6E). 
 
The acquired resistance to lapatinib and/or cisplatin is reversed by 
silencing MET.  
Parental SNU-216 cells showed a low level of MET expression, which 
notably increased in SNU-216 LR cells (Figure 2B). To investigate the role 
of MET in lapatinib resistance in SNU-216 LR cells, MET expression was 
downregulated by RNAi (Figure 7A). MET shRNA-transfected cells had a 
lower level of pAKT (Figure 7A) and also showed growth inhibition (Figure 
7B). Furthermore, MET silencing significantly suppressed lapatinib 
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resistance (Figure 7C) and cisplatin resistance (Figure 7D) compared to 
control shRNA cells. In addition, combination treatment showed additional 
growth inhibition compared to treatment with lapatinib alone in MET 
shRNA-transfected cells, but not in control shRNA cells (Figure 7E). 
 
HER2 and MET interplay through transcriptional control by FOXO1. 
To investigate whether interplay between HER2 and MET exists, stable 
SNU-216 LR3 and LR7 cell lines overexpressing either HER2 shRNA 
(Figure 8A) or MET shRNA (Figure 8D) were used. Western blot analysis 
showed that HER2 silencing decreased the protein expressions of total and 
phosphorylated MET (Figure 8A). In turn, MET silencing reduced the 
protein expressions of total and phosphorylated HER2 (Figure 8D). Thus, 
these findings indicate that there is a positive interplay between these two 
molecules. Then, the effect of HER2 downregulation on FOXO1 expression 
and activation was examined. Western blot analysis (Figure 8A) and 
luciferase reporter assay (Figure 8B) demonstrated that HER2 silencing 
increased protein expression and activation of FOXO1 without a change in 
FOXO1 mRNA expression as shown by RT-PCR (Figure 8C). Similar 
findings were observed in MET shRNA-transfected cells (Figure 8D-F). 
These results indicate that FOXO1 expression is negatively regulated at the 








Figure 2. Effect of chronic lapatinib treatment on SNU-216 cells. 
(A) Lapatinib-resistant (LR), HER2-positive GC cell lines (SNU-216 LR2-8) 
were generated from a lapatinib-sensitive, HER2-positive SNU-216 GC cell 
line by chronic exposure to lapatinib over a period of 8 months. Twenty-four 
hours after plating, parental and lapatinib-resistant SNU-216 cells were 
treated with the indicated concentrations of lapatinib for 3 days, and cell 
viability was determined using crystal violet assay. The percentage of viable 
cells is shown relative to untreated cells (considered as 100%). Each bar 
represents the mean ± s.d. * P < 0.05 versus parental SNU-216 cells. (B) 
Comparative analysis of total and phosphorylated HER2, MET and AKT as 
well as total FOXO1 by Western blot analysis (WT). mRNA expressions of 
HER2, MET and FOXO1 were determined by reverse transcription-
polymerase chain reaction (RT-PCR). β-actin protein and mRNA were 
served as loading controls. (C) FOXO1 transcriptional activity was 
determined by the luciferase reporter assay and was normalized by β-
galactosidase activity. Luciferase activity in parental SNU-216 cells was 
arbitrarily set to 1. Each bar represents the mean ± s.d. * P < 0.05 versus 

















Figure 3. Effect of FOXO1 overexpression on lapatinib sensitivity in 
lapatinib-resistant cell lines. 
SNU-216 LR3 and LR7 cells were transfected with empty pcDNA3 vector 
(pcDNA3) or FOXO1A3 mutant vector (FOXO1A3). Cell viability was 
measured by crystal violet assay. (A) FOXO1 overexpression was 
confirmed by Western blot analysis. (B) FOXO1 transcriptional activity was 
analyzed by the luciferase reporter assay. Each bar represents the mean ± 
s.d. * P < 0.05 versus pcDNA3 cells. (C) Cells were treated with the 
indicated concentrations of lapatinib, and cell viability was measured after 3 
days. The percentage of viable cells is shown relative to untreated cells 
(considered as 100%). Each bar represents the mean ± s.d. * P < 0.05 























Figure 4. Effect of FOXO1 on the cytotoxicity of cisplatin alone or 
combined with lapatinib in laptinib-resistant cell lines.  
Cell viability was measured by crystal violet assay. (A) Parental SNU-216 
cells and lapatinib-resistant SNU-216 cells (LR3 and LR7) were treated with 
cisplatin at the indicated concentration for 3 days. The percentage of viable 
cells is shown relative to untreated cells (considered as 100%). Each bar 
represents the mean ± s.d. *P < 0.05 versus parental cells. (B-C) SNU-216 
LR3 and LR7 cells were transfected with empty pcDNA3 vector (pcDNA3) 
or FOXO1A3 mutant vector (FOXO1A3). (B) Cells were treated with the 
indicated concentrations of cisplatin, and cell viability was measured after 3 
days. The percentage of viable cells is shown relative to untreated cells 
(considered as 100%). Each bar represents the mean ± s.d. * P < 0.05 
versus cisplatin-treated pcDNA3 cells. (C) Cells were treated with the 
1μmol/L lapatinib alone or combined with 10 μg/mL cisplatin, and cell 
viability was measured after 3 days. The percentage of viable cells is 
shown relative to untreated cells (considered as 100%). Each bar 
represents the mean ± s.d. * P < 0.05 versus pcDNA3 cells. †† P < 0.05 




















Figure 5. Association between FOXO1 and HER2/MET in lapatinib-
resistant cell lines. 
SNU-216 LR3 and LR7 cells were transfected with empty pcDNA3 vector 
(pcDNA3) or FOXO1A3 mutant vector (FOXO1A3). (A) The protein 
expressions of total and phosphorylated HER2, MET and AKT were 
determined by Western blot analysis (WT). (B) The mRNA expressions of 









Figure 6. Effect of HER2 downregulation on lapatinib/cisplatin 
resistance in lapatinib-resistant cell lines. 
SNU-216 LR3 and LR7 cells were infected with a lentivirus containing either 
control shRNA (shCtrl) or HER2 shRNA (shHER2). Cell viability was 
measured by crystal violet assay. (A) The protein expressions of HER2, 
pAKT and AKT were determined by Western blot analysis. (B) Twenty-four 
hours after plating, cells were cultured for 3 days and cell growth was 
determined at the indicated times. Each bar represents the mean ± s.d. * P 
< 0.05 versus shCtrl cells. (C) Cells were treated with the indicated 
concentrations of lapatinib, and cell viability was measured after 3 days. 
The percentage of viable cells is shown relative to untreated cells 
(considered as 100%). Each bar represents the mean ± s.d. * P < 0.05 
versus lapatinib-treated shCtrl cells. (D) Cells were treated with the 
indicated concentrations of cisplatin, and cell viability was measured after 3 
days. The percentage of viable cells is shown relative to untreated cells 
(considered as 100%). Each bar represents the mean ± s.d. * P < 0.05 
versus cisplatin-treated shCtrl cells. (E) Cells were treated with the 1μmol/L 
lapatinib alone or combined with 10 μg/mL cisplatin, and cell viability was 
measured after 3 days. The percentage of viable cells is shown relative to 
untreated cells (considered as 100%). Each bar represents the mean ± s.d. 









Figure 7. Effect of MET downregulation on lapatinib/cisplatin 
resistance in lapatinib-resistant cell lines. 
SNU-216 LR3 and LR7 cells were transfected with pGFP-v-RS vectors 
containing either control scrambled shRNA (shCtrl) or MET shRNA 
(shMET). Cell viability was measured by crystal violet assay. (A) The 
protein expressions of MET, pAKT and AKT were determined by Western 
blot analysis. (B) Cells were cultured for 3 days, and cell growth was 
determined at the indicated times. Each bar represents the mean ± s.d. * P 
< 0.05 versus shCtrl cells. (C) Cells were treated with the indicated 
concentrations of lapatinib and cell viability was measured after 3 days. The 
percentage of viable cells is shown relative to untreated cells (considered 
as 100%). Each bar represents the mean ± s.d. * P < 0.05 versus lapatinib-
treated shCtrl cells. (D) Cells were treated with the indicated concentrations 
of cisplatin, and cell viability was measured after 3 days. The percentage of 
viable cells is shown relative to untreated cells (considered as 100%). Each 
bar represents the mean ± s.d. * P < 0.05 versus cisplatin-treated shCtrl 
cells. (E) Cells were treated with the 1μmol/L lapatinib alone or combined 
with 10 μg/mL cisplatin, and cell viability was measured after 3 days. The 
percentage of viable cells is shown relative to untreated cells (considered 
as 100%). Each bar represents the mean ± s.d. * P < 0.05 versus shCtrl 














Figure 8. The relationships between HER2, MET and FOXO1 in 
lapatinib-resistant cells. 
(A-C) Cells were infected with a lentivirus containing either control shRNA 
(shCtrl) or HER2 shRNA (shHER2). (A) The expression and pMET, MET 
and FOXO1 protein expression were determined by Western blot analysis. 
(B) FOXO1 transcriptional activity was determined by the luciferase 
reporter assay. Each bar represents the mean ± s.d. * P < 0.05 versus 
parental shCtrl cells. (C) The mRNA expression of FOXO1 was evaluated 
by reverse transcription-polymerase chain reaction (RT-PCR). (D-F) Cells 
were transfected with pGFP-v-RS vectors containing either control 
scrambled shRNA (shCtrl) or MET shRNA (shMET). (D) The expression 
and pHER2, HER2 and FOXO1 protein expression were determined by 
Western blot analysis. (E) FOXO1 transcriptional activity was determined 
by the luciferase reporter assay. Each bar represents the mean ± s.d. * P < 
0.05 versus parental shCtrl cells. (F) mRNA expression of FOXO1 was 

















Figure 9. Model for FOXO1-dependent acquired lapatinib resistance 
and the crosstalk among FOXO1, HER2 and MET in lapatinib-resistant, 
HER2-positive GC cells. 
Downregulation of FOXO1 leads to coactivation of HER2 and MET, which 
are essential to lapatinib resistance. Reintroduction of FOXO1 is necessary 
to reduce the lapatinib resistance in a subpopulation of HER2-positive GC 




















The acquisition of drug resistance in treated patients has become a 
significant issue in the establishment of strategy for human cancer therapy. 
Moreover, the complex interplay of signal-transduction pathways further 
complicates customizing of cancer treatments which might target a single 
mechanism [21]. The purpose of the present study was to determine the 
correlation between FOXO1 expression profile and the sensitivity to 
lapatinib alone or in combination with cisplatin, thereby providing a new 
strategy for treating lapatinib-resistant, HER2-positive GC. Here, FOXO1 
suppression was identified as a determinant of acquired lapatinib resistance 
in HER2-positive GC cells, at least in part, through negative crosstalks with 
HER2 and MET. To the best of my knowledge, this is the first study to 
demonstrate the involvement of FOXO1 in anti-HER2 drug resistance and 
its association with MET in GC cells. 
 
Given that HER2 serves as a putative target for therapy in HER2-
positive GC, elucidating the molecular mechanism of lapatinib resistance is 
critical to establish a more efficient treatment strategy for patients who 
failed to respond to adjuvant trastuzumab-based chemotherapy. However, 
the molecular mechanism underlying the unresponsiveness of GC to 
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lapatinib remains largely unexplained. Previously, lapatinib sensitivity was 
shown to be positively correlated to the degree of HER2 overexpression in 
various cancer cells [23]. Consistently, lapatinib responsiveness was shown 
in HER2-positive parental GC cell lines SNU-216 and NCI-N87 [15]. 
Although the initially addicting oncoprotein HER2 in parental SNU-216 cells 
is the target of lapatinib, SNU-216 LR cells were lapatinib-resistant in spite 
of HER2 upregulation. This suggests that the acquired lapatinib resistance 
in SNU-216 LR cells may be attributed to an alternative or redundant 
survival pathway [46]. Indeed, Kim et al. [42] suggested that MET 
upregulation could confer the acquired lapatinib resistance to lapatinib-
sensitive, HER2-positive GC cells. 
 
Previous studies have shown that FOXO1 plays an important role in the 
regulation of responsiveness of cancer cells to various anticancer drugs 
[34-36]. For example, FOXO1 increased paclitaxel resistance in ovarian 
cancer cells [34], adriamycin resistance in breast cancer cells [35] and 
cisplatin resistance in GC cells [36]. With respect to HER2-positive cancer 
cells, FOXO1 decreased trastuzumab resistance in HER2-positive breast 
cancer cells [37, 38]. However, different resistance mechanisms have been 
reported for trastuzumab and lapatinib [47], and lapatinib sensitivity in 
cultured cells is determined by tissue type [48]. In the present study, 
FOXO1 activation was downregulated in SNU-216 LR cells compared to 
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parental SNU-216 cells. Thus, the present study hypothesized that FOXO1 
is implicated in the acquired lapatinib resistance in these cells in 
association with HER2 and MET. Taking advantage of lapatinib-resistant, 
HER2-posistive SNU-216 LR cell lines, I confirmed that lapatinib alone 
showed weak growth inhibitory effect toward SNU-216 LR cells. Further, 
FOXO1 overexpression in these cells induced an enhanced cytotoxic effect 
of lapatinib. These results demonstrate the importance of FOXO1 for the 
lapatinib-mediated cytotoxic effect in SNU-216 LR cells. 
 
The efficacy of lapatinib alone or in combination with standard 
chemotherapy for HER2-positive GC is yet to be improved. In the 
preclinical cell-based study using HER2-positive GC cell lines (SNU-216 
and NCI-N87), lapatinib plus chemotherapy showed an additive or 
synergistic effect [15]. In contrast, a randomized, open-labeled, phase III 
study (Tytan study) showed that second-line treatment of HER2-positive 
advanced GC patients with lapatinib plus chemotherapy did not significantly 
improve overall survival compared to chemotherapy alone [44]. In the 
present study, the combined treatment with lapatinib and cisplatin did not 
induce a significant difference in cell viability of SNU-216 LR cells 
compared to lapatinib treatment, which is consistent with results of the 
clinical trial. In the presence of FOXO1 overexpression, however, combined 
treatment resulted in a greater reduction in cell viability compared to 
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treatment with lapatinib alone. These results provides a direct evidence that 
FOXO1 suppression confers acquired resistance to lapatinib and/or 
cisplatin in lapatinib-resistant, HER2-positive GC cells. Since FOXO1 
involvement in lapatinib resistance has not been previously identified in 
HER2-positive cancers, this is a novel molecular mechanism underlying 
acquired lapatinib resistance in HER2-positive GC. These findings provide 
a basis for the proposal that systemic reintroduction of FOXO1 in HER2-
positive GC patients could result in a selective lapatinib toxicity in cancer 
cells. In the near future, it should be possible to generate an enhanced anti-
cancer effect via a combination of lapatinib and FOXO1-replacement 
therapy. However, the technique of transcription factor-replacement therapy 
is not yet in general use. 
 
The phenomenon of oncogene addiction has revealed potentially 
important therapeutic opportunities that can lead to the selective elimination 
of tumor cells showing dependence on a protein or pathway [46]. Just as 
acute inactivation of addicting oncoproteins frequently leads to cancer cell 
death, recent evidence points to similar outcomes induced by the 
reintroduction of a wild-type version of tumor suppressor genes that are 
frequently inactivated in cancer cells [46]. Accumulating data on the 
“addiction to lack of tumor suppressor genes” indicate that, in the 
establishment of the oncogene addicted state, a prerequisite may involve 
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the removal of support systems such as tumor suppressors (p53, FHIT, 
PTEN, LKB1 and TESTIN) [46]. In the present study using SNU-216 LR 
cells, upregulations of oncogenes HER2 and MET as well as 
downregulation of tumor suppressor FOXO1 were observed. In addition, 
FOXO1 overexpression reduced mRNA expressions of HER2 and MET. 
Accordingly, it seems that chronic exposure to lapatinib induced FOXO1 
downregulation, and consequently upregulated of HER2 and MET through 
transcriptional control. Taken together, I speculate that FOXO1 inactivation 
may be a prerequisite in the establishment of the addiction to HER2 as well 
as MET in SNU-216 LR cells.  
 
Although lapatinib responsiveness is associated with HER2 
overexpression in parental GC cell lines [15], HER2 was upregulated in 
lapatinib-resistant, HER2-positive GC cell lines in the present study. 
However, the effect of HER2 modulation on the acquired lapatinib 
resistance in these cells has never been evaluated. This study investigated 
whether the loss of HER2 addiction or addiction switching to an alternative 
oncogene [46] is induced by chronic exposure to lapatinib. HER2 
expression in SNU-216 LR cells was downregulated by using RNA 
interference, which resulted in AKT inactivation and cell growth suppression. 
These results indicate that HER2 addiction still remains. Inconsistently, 
HER2 downregulation significantly suppressed resistance to an anti-HER2 
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drug lapatinib. In addition, cisplatin resistance was decreased in HER2-
silenced SNU-216 LR cells, which is consistent with a previous report [49]. 
 
MET has been shown to cross-react with EGFR proteins and possibly 
substitutes for their activity, thus conferring resistance to EGFR-targeting 
drugs [50]. With respect to GC cells, HGF-induced MET activation in HER2-
positive GC cell lines (SNU-216 and NCI-N87) induced lapatinib resistance 
[23]. In the present and previous [42] studies, chronic exposure to lapatinib 
upregulated MET compared to parental HER2-positive GC cells. However, 
the effect of MET modulation on the acquired lapatinib resistance in these 
cells has not been shown. This study examined whether cancer cells exhibit 
MET addiction in addition to original HER2 addiction. MET downregulation 
in SNU-216 LR cells decreased AKT activation and cell growth, which was 
similar to results obtained with HER2 downregulation. Consistently, MET 
downregulation significantly suppressed lapatinib and/or cisplatin resistance. 
Since both HER2 and MET contributed to lapatinib resistance in SNU-216 
LR cells, it seems that MET provides redundant survival signals through the 
activation of downstream survival pathways that overlap with those of 
HER2. Thus, SNU-216 LR cells can be considered to be “co-addicted” to 
HER2 and MET. 
 
The present study showed that MET expression and activation were 
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clearly lower than those of HER2 in parental SNU-216 cells. After 
acquisition of lapatinib resistance, MET was notably upregulated in the 
majority of SNU-216 LR cell lines compared to HER2. Previously, MET 
amplification was shown to be responsible for the MET overexpression 
induced by EGFR RTK inhibitor treatment of NSCLC patients who 
displayed acquired resistance [46]. However, Kim et al. [42] reported that 
there is no MET gene amplification in HER2-positive SNU-216 LR cells with 
acquired lapatinib resistance. Although concomitant overexpression of 
HER2 and MET was observed in a subset of GC patients [22], the 
regulatory relationship between these two molecules has not been 
demonstrated in GC. My results showed that HER2 downregulation in SNU-
216 LR cells suppressed the expressions of both total and phosphorylated 
MET and vice versa. Thus, it seems that the interplay between these two 
molecules in the survival signaling pathway is not due to 
transphosphorylation, instead is due to the activations of overlapping 
downstream molecules. Since FOXO1 is negatively controlled by and 
controls HER2 and MET, FOXO1 seems to serve as an important linker 
between HER2 and MET signaling pathways via negative crosstalks. In 
addition, downregulation of either HER2 or MET increased FOXO1 protein 
expression and activation, but not mRNA expression, which indicates 




In conclusion, the present study shows a novel molecular mechanism 
that could cause the acquired lapatinib resistance in a subset of HER2-
positive GC cells. It seems that FOXO1 suppression is implicated in the 
acquisition of lapatinib resistance in HER2-positive GC cells through 
upregulation of MET as well as HER2. Thus, this should be taken into 
consideration when designing combination therapies for a subset of 
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국 문 초 록 
 
목적: Lapatinib은 human epidermal growth factor receptor 2 
(HER2)의 과발현을 보이는 암환자의 치료에 사용되는 표적치료제로서, 
trastuzumab 내성을 나타내는 경우에 사용이 시도되고 있다. 그러나 
위암의 경우에는 내성으로 인하여 lapatinib의 효용성이 의심되고 
있으나, 그 내성기전에 대한 연구는 현재로서 미진한 실정이다. 본 
연구에서는 전사인자인 forkhead box O 1 (FOXO1)이 위암세포의 
lapatinib 내성기전에 관여하는지를 관찰하고자 하였다.  
 
실험방법: HER2 과발현 위암세포주 (SNU-216)로부터 7개의 lapatinib 
내성세포주 (SNU-216 LR2-8)를 확립한 후, 그 중 2개의 세포주 
(SNU-216 LR3과 SNU-216 LR7)에 유전자이입 방법을 사용하여 
FOXO1과 HER2 그리고 MET의 발현 변화를 유도하였다. Lapatinib을 
단독 또는 cisplatin과 병용하여 이 세포들에 투여한 후 crystal violet 
assay를 실시하여 세포의 항암제 내성을 측정하였고, Western blot 






결과: Lapatinib 내성세포주의 대부분 (SNU-216 LR3-8)에서 SNU-
216에 비하여 HER2와 MET의 발현은 증가하였지만, FOXO1의 활성은 
감소하였고 SNU-216 LR2 세포주의 경우 HER2의 발현증가는 
뚜렷하게 관찰되지 않았다. FOXO1의 발현을 증가시킨 2개의 lapatinib 
내성세포주에서는 lapatinib과 cisplatin에 대한 내성의 감소가 
관찰되었으며, HER2와 MET의 전사가 감소되었다. HER2와 MET는 
lapatinib 또는 cisplatin과의 병용 투여에 대한 내성을 증가시켰으며, 
서로 positive crosstalk를 나타내었고, 공통적으로 FOXO1의 발현을 
전사 후 단계에서 억제하였다.  
 
결론: 본 연구는 FOXO1이 HER2 및 MET와의 상호적인 negative 
crosstalk를 통하여 lapatinib에 대한 획득 내성을 조절하는데 중추적인 
역할을 수행함을 관찰하였다. 따라서, 이 결과는 HER2 과발현 위암환자 
중 lapatinib 내성을 나타내는 환자에게 필요한 표적치료제의 개발에 
유용한 정보를 제공할 것으로 사료된다.  
 
주요어: 위암; HER2; lapatinib 내성; FOXO1; MET 
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